NASDAQ:TSBX Turnstone Biologics (TSBX) Stock Price, News & Analysis $2.55 +0.04 (+1.59%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.48▼$2.5950-Day Range$2.24▼$2.9952-Week Range$1.63▼$13.20Volume22,022 shsAverage Volume139,923 shsMarket Capitalization$58.98 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Turnstone Biologics alerts: Email Address Turnstone Biologics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside645.1% Upside$19.00 Price TargetShort InterestHealthy1.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.44) to ($3.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.67 out of 5 starsMedical Sector269th out of 936 stocksBiological Products, Except Diagnostic Industry35th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingTurnstone Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTurnstone Biologics has received no research coverage in the past 90 days.Read more about Turnstone Biologics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.06% of the float of Turnstone Biologics has been sold short.Short Interest Ratio / Days to CoverTurnstone Biologics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Turnstone Biologics has recently decreased by 72.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTurnstone Biologics does not currently pay a dividend.Dividend GrowthTurnstone Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSBX. Previous Next 3.3 News and Social Media Coverage News SentimentTurnstone Biologics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Turnstone Biologics this week, compared to 0 articles on an average week.Search Interest2 people have searched for TSBX on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Turnstone Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders32.10% of the stock of Turnstone Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.51% of the stock of Turnstone Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Turnstone Biologics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Turnstone Biologics are expected to grow in the coming year, from ($3.44) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Turnstone Biologics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Turnstone Biologics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTurnstone Biologics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Turnstone Biologics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...Click here now to claim your FREE copy of Marc's AI playbook. About Turnstone Biologics Stock (NASDAQ:TSBX)Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.Read More TSBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSBX Stock News HeadlinesJuly 19, 2024 | americanbankingnews.comTurnstone Biologics (NASDAQ:TSBX) versus Adaptimmune Therapeutics (NASDAQ:ADAP) Financial SurveyMay 26, 2024 | uk.investing.comPiper Sandler reaffirms Overweight rating on Turnstone Biologics sharesJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."May 16, 2024 | markets.businessinsider.comLeerink Partners Reaffirms Their Hold Rating on Turnstone Biologics Corp. (TSBX)May 13, 2024 | investorplace.comTSBX Stock Earnings: Turnstone Biologics Misses EPS for Q1 2024May 13, 2024 | globenewswire.comTurnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business HighlightsMay 11, 2024 | finance.yahoo.comTurnstone Biologics Corp. (TSBX)May 8, 2024 | globenewswire.comTurnstone Biologics to Present at the 2024 Bank of America Securities Health Care ConferenceJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."April 18, 2024 | uk.investing.comTurnstone Biologics announces board member resignationApril 16, 2024 | globenewswire.comTurnstone Biologics Appoints William Waddill to its Board of DirectorsApril 12, 2024 | seekingalpha.comTSBX Turnstone Biologics Corp.March 22, 2024 | investorplace.comTSBX Stock Earnings: Turnstone Biologics Beats EPS for Q4 2023March 21, 2024 | globenewswire.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business HighlightsMarch 2, 2024 | finance.yahoo.comTurnstone Biologics Corp. (NASDAQ:TSBX) institutional investors have had a good week as stock gains 34%February 23, 2024 | benzinga.comTurnstone Biologics Stock (NASDAQ:TSBX), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comTurnstone Biologics to Participate in Upcoming Investor ConferencesFebruary 21, 2024 | globenewswire.comTurnstone Biologics to Participate in Upcoming Investor ConferencesSee More Headlines Receive TSBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Turnstone Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/27/2024Next Earnings (Estimated)9/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSBX CUSIPN/A CIK1764974 Webturnstonebio.com Phone347-897-5988FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$20.00 Low Stock Price Target$18.00 Potential Upside/Downside+645.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($10.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,200,000.00 Net MarginsN/A Pretax Margin-287.40% Return on Equity-174.96% Return on Assets-72.80% Debt Debt-to-Equity RatioN/A Current Ratio6.72 Quick Ratio6.72 Sales & Book Value Annual Sales$19.31 million Price / Sales3.05 Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book0.60Miscellaneous Outstanding Shares23,130,000Free Float15,704,000Market Cap$58.98 million OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Sammy J. Farah M.B.A. (Age 51)Ph.D., President, CEO & Director Comp: $820.88kDr. Venkat Ramanan Ph.D. (Age 54)Chief Financial Officer Comp: $613.14kDr. Vijay Chiruvolu M.B.A. (Age 62)Ph.D., Interim Chief Technology Officer Comp: $548.43kDr. Michael F. Burgess M.D. (Age 60)MBChB, Ph.D., Interim Chief Medical Officer & Executive Director Dr. Stewart Abbot Ph.D. (Age 57)Chief Scientific Officer Ms. Saryah Azmat (Age 34)Chief Business Officer Comp: $479.73kMore ExecutivesKey CompetitorsGeneration BioNASDAQ:GBIOChromaDexNASDAQ:CDXCXBiotechNASDAQ:XBIT23andMeNASDAQ:MEShattuck LabsNASDAQ:STTKView All CompetitorsInstitutional OwnershipZimmer Partners LPBought 130,826 shares on 5/17/2024Ownership: 0.774%View All Institutional Transactions TSBX Stock Analysis - Frequently Asked Questions How have TSBX shares performed this year? Turnstone Biologics' stock was trading at $2.55 at the start of the year. Since then, TSBX shares have increased by 0.0% and is now trading at $2.55. View the best growth stocks for 2024 here. How were Turnstone Biologics' earnings last quarter? Turnstone Biologics Corp. (NASDAQ:TSBX) announced its quarterly earnings results on Monday, May, 13th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.07. When did Turnstone Biologics IPO? Turnstone Biologics (TSBX) raised $80 million in an initial public offering (IPO) on Friday, July 21st 2023. The company issued 6,666,667 shares at $12.00 per share. How do I buy shares of Turnstone Biologics? Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TSBX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turnstone Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
